<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601170</url>
  </required_header>
  <id_info>
    <org_study_id>2-102-05-019</org_study_id>
    <nct_id>NCT02601170</nct_id>
  </id_info>
  <brief_title>Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tri-Service General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe hemophilia is characterized by frequent and lifelong bleeding, with more than 60% of&#xD;
      bleeds occurring into joints . Repeated joint bleeding leads to chronic synovitis, cartilage&#xD;
      damage and bony destruction. Currently available treatment of hemophilic arthropathy, such as&#xD;
      analgesics, NSAIDs, and hyaluronic acid (HA), are predominantly directed toward the&#xD;
      symptomatic relief of pain and inflammation, but they do little to reduce joint cartilage&#xD;
      degeneration.&#xD;
&#xD;
      Platelet-Rich Plasma (PRP) is a simple and minimally invasive method that provides a natural&#xD;
      concentrate of autologous growth factors from the blood. This method is now being&#xD;
      increasingly applied in clinical practice to treat musculoskeletal disorders, such as tendon&#xD;
      repairment and osteoarthritis. To the best of our knowledge, no study applies PRP for&#xD;
      arthropathy of knee joint in hemophilia patients. The aim of the study is to investigate the&#xD;
      efficacy, safety and duration of benefit of single PRP injection versus five weekly&#xD;
      intra-articular injections of HA in patients with hemophilic arthropathy of knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe haemophilia is characterized by frequent and lifelong bleeding, with more than 60% of&#xD;
      bleeds occurring into joints. Repeated joint bleeding leads to chronic synovitis, cartilage&#xD;
      damage and bony destruction, which are associated with limitation of range of motion (ROM),&#xD;
      pain, muscle atrophy, functional impairment, and poor quality of life. The knee, elbow, and&#xD;
      ankle are the most commonly involved joints and arthropathy could worsen in adolescence or&#xD;
      young adulthood. Hemophilic arthropathy is a multifactorial event and there is evidence to&#xD;
      suggest that iron may play a major role with release of cytokines such as Interleukin (&#xD;
      IL)-1, IL-6, and tumour necrosis factor alpha (TNF-α) leading to chronic proliferative&#xD;
      synovitis, hypervascularity, and progressive arthropathy. These effects on cartilage and&#xD;
      subchondral bone are inflammatory and degenerative in nature and management of chronic&#xD;
      hemophilic arthropathy is difficult.&#xD;
&#xD;
      Currently available drugs for the treatment of hemophilic arthropathy, such as analgesics,&#xD;
      corticosteroids, nonsteroid and steroid anti-inflammatory drugs, and hyaluronic acid (HA),&#xD;
      are predominantly directed toward the symptomatic relief of pain and inflammation, but they&#xD;
      do little to reduce joint cartilage degeneration.&#xD;
&#xD;
      Platelet Rich Plasma (PRP) is a simple and minimally invasive method that provides a natural&#xD;
      concentrate of autologous growth factors from the blood. This method is now being&#xD;
      increasingly applied in clinical practice to treat musculoskeletal disorders, such as tendon&#xD;
      repairment and osteoarthritis. Growth factors including platelet derived growth factor&#xD;
      (PDGF), insulin growth factor (IGF), vascular endothelial growth factor, and transforming&#xD;
      growth factor beta-1 are believed to be key components of PRP for structural repair. Although&#xD;
      comparing PRP with other intra-articular and soft tissue injections has led to conflicting&#xD;
      results, it seems that PRP has useful effects on healing and functional improvement of&#xD;
      injured tissues. To the best of our knowledge, only one study applies PRP for arthropathy in&#xD;
      haemophilia. Teyssler et al reported PRP could reduce pain of chronic ankle synovitis in&#xD;
      hemophilia although the small sample size (n=6), short term follow-up and absence of a&#xD;
      control group.&#xD;
&#xD;
      Hyaluronic acid (HA) has some role in joint mechanical support and its metabolic effects,&#xD;
      which causes endogenous HA synthesis, stimulation of chondrocyte metabolism, synthesis of&#xD;
      cartilage matrix components, and inhibition of chondrodegenerative enzymes, as well as&#xD;
      inflammatory process. In 1994 Fernandez-Palazzi et al firstly used intra-articular HA&#xD;
      injection for haemophiliacs with arthropathy and reported its beneficial effects in 2002.&#xD;
      Recently, Carulli et al reported 27 haemophilic patients with a mean seven-year follow-up who&#xD;
      had excellent results in terms of pain relief and functional improvement in the knee&#xD;
      following treatment with HA injection. Viscosupplementation is a safe and effective&#xD;
      therapeutic strategy in haemophilic arthropathy of knee in order to delay of surgery.&#xD;
&#xD;
      The aim of the study was to investigate the efficacy, safety and duration of benefit of&#xD;
      single PRP injection versus five weekly intra-articular injections of HA in patients with&#xD;
      haemophilic arthropathy of knee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &amp;6 Months</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
    <description>The pain intensity will be evaluated subjectively on a visual analogue scale (0-10).&#xD;
Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) From Baseline at 1, 2, 3 &amp;6 Months</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
    <description>It consists of 24 items: five pertaining to pain perception, two to stiffness, and 17 to physical function.&#xD;
Individual scores were then summed to form a raw score ranging from 0 (best) to 2400 (worst). Finally, WOMAC total score normalized between 0 (best) and 100 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) From Baseline at 1, 2, 3 &amp;6 Months</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
    <description>The SF-36 is a 36-item assessment tool that measures eight general health concepts including physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality, social functioning, role limitation due to emotional problems, and mental health. Individual scores were then summed to form a total score ranging from 0 (worst) to 100 (best). Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasonographic Synovial Thickness (mm) and Change From Baseline at 1, 2, 3 &amp;6 Months</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
    <description>Synovial thickness (mm) by ultrasonography were evaluated from the lateral, middle, and medial aspects of the anterior suprapatellar recess</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synovial Hyperemia (Score) and Change From Baseline at 1, 2, 3 &amp;6 Months</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
    <description>Power Doppler assessment of the selected synovial sites was performed with settings standardized to a pulse repetition frequency of 700 Hz. The power Doppler gain was adjusted to a level just below the disappearance of artifacts under the bony cortex.14,15 The intensity of blood flow in the synovium was scored on a semiquantitative scale from 0-3 (grade 0, no intraarticular colour signal; grade 1, up to 3 color signals or 2 single and 1 confluent signal in the intraarticular area; grade 2, greater than grade 1 to &lt;50% of the intraarticular area filled with color signals; grade 3, ≥50% of the intraarticular area filled with color signals)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion (ROM, Degrees) From Baseline at 1, 2, 3 &amp;6 Months</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemarthrosis From Baseline at 1, 2, 3 &amp;6 Months</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
    <description>Episode(s) of hemarthrosis in the previous one month</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hemophilia</condition>
  <condition>Hemophilic Arthropathy</condition>
  <arm_group>
    <arm_group_label>PRP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet-Rich Plasma Intra-Articular Injection</intervention_name>
    <arm_group_label>PRP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid Viscosupplementation</intervention_name>
    <arm_group_label>HA Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hemophilia patients with hemophilic arthropathy of knee joints for at least 6 months&#xD;
&#xD;
          -  painful (VAS ≥ 3) hemophilic arthropathy of knee joints after medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of joint infections, any surgery on the joint in preceding 12 months&#xD;
&#xD;
          -  intra-articular corticosteroid or HA injection within the past 6 months&#xD;
&#xD;
          -  treatment with systemic steroids&#xD;
&#xD;
          -  history of rheumatoid arthritis, or gouty arthropathy&#xD;
&#xD;
          -  history of chicken or egg allergy&#xD;
&#xD;
          -  presence of neoplasm&#xD;
&#xD;
          -  use of non steroidal anti-inflammatory drugs in the 5 days before study&#xD;
&#xD;
          -  platelet values &lt; 100,000/mm3&#xD;
&#xD;
          -  acute hemarthrosis&#xD;
&#xD;
          -  paresis, or recent trauma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 7, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <results_first_submitted>November 9, 2016</results_first_submitted>
  <results_first_submitted_qc>August 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>August 29, 2020</last_update_submitted>
  <last_update_submitted_qc>August 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tri-Service General Hospital</investigator_affiliation>
    <investigator_full_name>Tsung-Ying Li</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>Platelet Rich Plasma</keyword>
  <keyword>Hemophilia</keyword>
  <keyword>Hemophilic arthropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PRP Group</title>
          <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
        </group>
        <group group_id="P2">
          <title>HA Group</title>
          <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PRP Group</title>
          <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
        </group>
        <group group_id="B2">
          <title>HA Group</title>
          <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="2.3"/>
                    <measurement group_id="B2" value="38.8" spread="2.4"/>
                    <measurement group_id="B3" value="40.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &amp;6 Months</title>
        <description>The pain intensity will be evaluated subjectively on a visual analogue scale (0-10).&#xD;
Higher scores mean a worse outcome.</description>
        <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRP Group</title>
            <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
          </group>
          <group group_id="O2">
            <title>HA Group</title>
            <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &amp;6 Months</title>
          <description>The pain intensity will be evaluated subjectively on a visual analogue scale (0-10).&#xD;
Higher scores mean a worse outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.6"/>
                    <measurement group_id="O2" value="4.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.8"/>
                    <measurement group_id="O2" value="1.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.8"/>
                    <measurement group_id="O2" value="1.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.8"/>
                    <measurement group_id="O2" value="2.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.7"/>
                    <measurement group_id="O2" value="3.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) From Baseline at 1, 2, 3 &amp;6 Months</title>
        <description>It consists of 24 items: five pertaining to pain perception, two to stiffness, and 17 to physical function.&#xD;
Individual scores were then summed to form a raw score ranging from 0 (best) to 2400 (worst). Finally, WOMAC total score normalized between 0 (best) and 100 (worst).</description>
        <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRP Group</title>
            <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
          </group>
          <group group_id="O2">
            <title>HA Group</title>
            <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) From Baseline at 1, 2, 3 &amp;6 Months</title>
          <description>It consists of 24 items: five pertaining to pain perception, two to stiffness, and 17 to physical function.&#xD;
Individual scores were then summed to form a raw score ranging from 0 (best) to 2400 (worst). Finally, WOMAC total score normalized between 0 (best) and 100 (worst).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="3.4"/>
                    <measurement group_id="O2" value="33.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="3.7"/>
                    <measurement group_id="O2" value="19.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="3.3"/>
                    <measurement group_id="O2" value="21.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="3.9"/>
                    <measurement group_id="O2" value="27.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="3.7"/>
                    <measurement group_id="O2" value="35.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form-36 (SF-36) From Baseline at 1, 2, 3 &amp;6 Months</title>
        <description>The SF-36 is a 36-item assessment tool that measures eight general health concepts including physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality, social functioning, role limitation due to emotional problems, and mental health. Individual scores were then summed to form a total score ranging from 0 (worst) to 100 (best). Higher scores mean a better outcome.</description>
        <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRP Group</title>
            <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
          </group>
          <group group_id="O2">
            <title>HA Group</title>
            <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form-36 (SF-36) From Baseline at 1, 2, 3 &amp;6 Months</title>
          <description>The SF-36 is a 36-item assessment tool that measures eight general health concepts including physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality, social functioning, role limitation due to emotional problems, and mental health. Individual scores were then summed to form a total score ranging from 0 (worst) to 100 (best). Higher scores mean a better outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" spread="5.3"/>
                    <measurement group_id="O2" value="54.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" spread="4.6"/>
                    <measurement group_id="O2" value="58.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" spread="4.1"/>
                    <measurement group_id="O2" value="63.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="4.7"/>
                    <measurement group_id="O2" value="63.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" spread="3.7"/>
                    <measurement group_id="O2" value="58.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ultrasonographic Synovial Thickness (mm) and Change From Baseline at 1, 2, 3 &amp;6 Months</title>
        <description>Synovial thickness (mm) by ultrasonography were evaluated from the lateral, middle, and medial aspects of the anterior suprapatellar recess</description>
        <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRP Group</title>
            <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
          </group>
          <group group_id="O2">
            <title>HA Group</title>
            <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Ultrasonographic Synovial Thickness (mm) and Change From Baseline at 1, 2, 3 &amp;6 Months</title>
          <description>Synovial thickness (mm) by ultrasonography were evaluated from the lateral, middle, and medial aspects of the anterior suprapatellar recess</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="1.3"/>
                    <measurement group_id="O2" value="6.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="1.0"/>
                    <measurement group_id="O2" value="6.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="1.3"/>
                    <measurement group_id="O2" value="6.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.2"/>
                    <measurement group_id="O2" value="6.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="1.0"/>
                    <measurement group_id="O2" value="6.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Synovial Hyperemia (Score) and Change From Baseline at 1, 2, 3 &amp;6 Months</title>
        <description>Power Doppler assessment of the selected synovial sites was performed with settings standardized to a pulse repetition frequency of 700 Hz. The power Doppler gain was adjusted to a level just below the disappearance of artifacts under the bony cortex.14,15 The intensity of blood flow in the synovium was scored on a semiquantitative scale from 0-3 (grade 0, no intraarticular colour signal; grade 1, up to 3 color signals or 2 single and 1 confluent signal in the intraarticular area; grade 2, greater than grade 1 to &lt;50% of the intraarticular area filled with color signals; grade 3, ≥50% of the intraarticular area filled with color signals)</description>
        <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRP Group</title>
            <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
          </group>
          <group group_id="O2">
            <title>HA Group</title>
            <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Hyperemia (Score) and Change From Baseline at 1, 2, 3 &amp;6 Months</title>
          <description>Power Doppler assessment of the selected synovial sites was performed with settings standardized to a pulse repetition frequency of 700 Hz. The power Doppler gain was adjusted to a level just below the disappearance of artifacts under the bony cortex.14,15 The intensity of blood flow in the synovium was scored on a semiquantitative scale from 0-3 (grade 0, no intraarticular colour signal; grade 1, up to 3 color signals or 2 single and 1 confluent signal in the intraarticular area; grade 2, greater than grade 1 to &lt;50% of the intraarticular area filled with color signals; grade 3, ≥50% of the intraarticular area filled with color signals)</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.3"/>
                    <measurement group_id="O2" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Range of Motion (ROM, Degrees) From Baseline at 1, 2, 3 &amp;6 Months</title>
        <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRP Group</title>
            <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
          </group>
          <group group_id="O2">
            <title>HA Group</title>
            <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Range of Motion (ROM, Degrees) From Baseline at 1, 2, 3 &amp;6 Months</title>
          <units>degree</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="8.5"/>
                    <measurement group_id="O2" value="90.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="7.6"/>
                    <measurement group_id="O2" value="91.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.3" spread="7.9"/>
                    <measurement group_id="O2" value="91.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.4" spread="7.8"/>
                    <measurement group_id="O2" value="91.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.9" spread="8.5"/>
                    <measurement group_id="O2" value="91.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemarthrosis From Baseline at 1, 2, 3 &amp;6 Months</title>
        <description>Episode(s) of hemarthrosis in the previous one month</description>
        <time_frame>baseline, 1 month, 2 months, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRP Group</title>
            <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
          </group>
          <group group_id="O2">
            <title>HA Group</title>
            <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Hemarthrosis From Baseline at 1, 2, 3 &amp;6 Months</title>
          <description>Episode(s) of hemarthrosis in the previous one month</description>
          <units>episode (s)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.2"/>
                    <measurement group_id="O2" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.3"/>
                    <measurement group_id="O2" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PRP Group</title>
          <description>single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)&#xD;
Platelet-Rich Plasma Intra-Articular Injection</description>
        </group>
        <group group_id="E2">
          <title>HA Group</title>
          <description>five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).&#xD;
Hyaluronic Acid Viscosupplementation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tsung-Ying Li</name_or_title>
      <organization>Tri-service general hospital</organization>
      <phone>886-2-87927166</phone>
      <email>doc31141@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

